Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6.
作者信息
Thurman Morgan, van Doorn Jacob, Danzer Barbara, Webb Thomas R, Stamm Stefan
机构信息
University of Kentucky, Lexington, KY, USA.
出版信息
Biomark Insights. 2017 Sep 12;12:1177271917730557. doi: 10.1177/1177271917730557. eCollection 2017.
OBJECTIVE
The aim of the study was to define pharmacodynamic markers for sudemycin D6, an experimental cancer drug that changes alternative splicing in human blood.
METHODS
Blood samples from 12 donors were incubated with sudemycin D6 for up to 24 hours, and at several time points total RNA from lymphocytes was prepared and the pre-messenger RNA (mRNA) splicing patterns were analyzed with reverse transcription-polymerase chain reaction.
RESULTS
Similar to immortalized cells, blood lymphocytes change alternative splicing due to sudemycin D6 treatment. However, lymphocytes in blood respond slower than immortalized cultured cells.
CONCLUSIONS
Exon skipping in the and pre-mRNAs are pharmacodynamic markers for sudemycin D6 treatment and show effects beginning at 9 hours after treatment.
Zotero 插件